ArticleNature communications2023
Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Sea nettle jellyfish venom targets proteoglycans to cause cell death and pain.Science advances · 2026Article
- Dissecting conserved molecular mechanisms of biological toxin activity through CRISPR screening.Biochemical Society transactions · 2026Review
- Posaconazole mitigates α-amanitin-induced liver injury by inhibiting STT3B-mediated glycosylation and cellular uptake.Frontiers in pharmacology · 2026Article
- Applications of Genome-wide Screening of CRISPR/Cas9 Knockout Library in Identifying Novel Molecular Targets for Xenobiotics.Environment & health (Washington, D.C.) · 2025Review
- Knowledge, attitude, and practice on mushroom poisoning among residents of Jilin province.BMC public health · 2025Article
- Studies on the Emission of Volatile Organic Compounds from Selected Forest Mushrooms of the GenusMolecules (Basel, Switzerland) · 2025Article
- MTCH2 Suppresses Thermogenesis by Regulating Autophagy in Adipose Tissue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Advances in molecular epidemiology of diabetic retinopathy: from genomics to gut microbiomics.Molecular biology reports · 2025Review
- Serum metabolomics identifies novel prognostic biomarkers inFrontiers in pharmacology · 2025Article
- Comparative analysis of VP1 epitopic variation among different isolates of foot-and-mouth disease virus type-O during an outbreak in the Punjab province of Pakistan.Veterinary research forum : an international quarterly journal · 2025Article
- Article
- Review
- Integrating genome-wide CRISPR screens and in silico drug profiling for targeted antidote development.Nature protocols · 2024Review
- Myocardial injury caused byWorld journal of emergency medicine · 2024Article
- A Sensitive, Cell-Based Assay for Measuring Low-Level Biological Activity of α-Amanitin.International journal of molecular sciences · 2023Article
- Amanitins: The Most Poisonous Molecules of the Fungal World.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The "death cap", Amanita phalloides, is the world's most poisonous mushroom, responsible for 90% of mushroom-related fatalities. The most fatal component of the death cap is α-amanitin. Despite its lethal effect, the exact mechanisms of how α-amanitin poisons humans remain unclear, leading to no specific antidote available for treatment. Here we show that STT3B is required for α-amanitin toxicity and its inhibitor, indocyanine green (ICG), can be used as a specific antidote. By combining a genome-wide CRISPR screen with an in silico drug screening and in vivo functional validation, we discover that N-glycan biosynthesis pathway and its key component, STT3B, play a crucial role in α-amanitin toxicity and that ICG is a STT3B inhibitor. Furthermore, we demonstrate that ICG is effective in blocking the toxic effect of α-amanitin in cells, liver organoids, and male mice, resulting in an overall increase in animal survival. Together, by combining a genome-wide CRISPR screen for α-amanitin toxicity with an in silico drug screen and functional validation in vivo, our study highlights ICG as a STT3B inhibitor against the mushroom toxin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.